Weekly rate ratios among children aged 5–17 comparing lowest COVID-19 vaccination coverage quartile states to highest coverage quartile states by outcome: December 13, 2020–April 30, 2022.

Vaccine coverage estimates for children aged 5–17 years during the first and last week of the Delta and Omicron periods of predominance in the US: (Delta: 9.21% as of the week of June 20th, 2021, 22.57% the week of October 31, 2021); (Omicron: 29.19% the week of December 19, 2021, 40.03% the week of April 24, 2022). Full vaccination coverage ranges for bottom and top quartile states as of the week of April 24, 2022: Bottom quartile: 20.14%–28.46%, Top quartile: 47.24%–59.42%.</p

Weekly “fully vaccinated” pediatric vaccination coverage rates by age group among children aged 5–17 years, U.S., from December 13, 2020, through April 30, 2022.

Weekly “fully vaccinated” pediatric vaccination coverage rates by age group among children aged 5–17 years, U.S., from December 13, 2020, through April 30, 2022.</p

Rate ratios among children aged 5–17 years by outcome comparing COVID-19 pediatric vaccination coverage quartiles of states to states in the highest vaccination coverage quartile during Delta and Omicron predominant periods–by age group and overall.

Rate ratios among children aged 5–17 years by outcome comparing COVID-19 pediatric vaccination coverage quartiles of states to states in the highest vaccination coverage quartile during Delta and Omicron predominant periods–by age group and overall.</p

Complete vaccination coverage ranges by state coverage quartile for midpoints^a of Delta and Omicron predominant time periods.

Complete vaccination coverage ranges by state coverage quartile for midpointsa of Delta and Omicron predominant time periods.</p

Number and rates of COVID-19 cases, emergency department (ED) visits, and hospital admissions in the United States during the Delta and Omicron periods, by age group and overall (5–17 years).

(DOCX)</p

Demographic characteristics and county classification breakdowns for jurisdictions included vs. excluded for COVID-19 cases.

(DOCX)</p

Table1_Prevalence of concomitant rheumatologic diseases and autoantibody specificities among racial and ethnic groups in SLE patients.docx

ObjectiveLeveraging the Manhattan Lupus Surveillance Program (MLSP), a population-based registry of cases of systemic lupus erythematosus (SLE) and related diseases, we investigated the proportion of SLE with concomitant rheumatic diseases, including Sjögren’s disease (SjD), antiphospholipid syndrome (APLS), and fibromyalgia (FM), as well as the prevalence of autoantibodies in SLE by sex and race/ethnicity.MethodsPrevalent SLE cases fulfilled one of three sets of classification criteria. Additional rheumatic diseases were defined using modified criteria based on data available in the MLSP: SjD (anti-SSA/Ro positive and evidence of keratoconjunctivitis sicca and/or xerostomia), APLS (antiphospholipid antibody positive and evidence of a blood clot), and FM (diagnosis in the chart).Results1,342 patients fulfilled SLE classification criteria. Of these, SjD was identified in 147 (11.0%, 95% CI 9.2–12.7%) patients with women and non-Latino Asian patients being the most highly represented. APLS was diagnosed in 119 (8.9%, 95% CI 7.3–10.5%) patients with the highest frequency in Latino patients. FM was present in 120 (8.9%, 95% CI 7.3–10.5) patients with non-Latino White and Latino patients having the highest frequency. Anti-dsDNA antibodies were most prevalent in non-Latino Asian, Black, and Latino patients while anti-Sm antibodies showed the highest proportion in non-Latino Black and Asian patients. Anti-SSA/Ro and anti-SSB/La antibodies were most prevalent in non-Latino Asian patients and least prevalent in non-Latino White patients. Men were more likely to be anti-Sm positive.ConclusionData from the MLSP revealed differences among patients classified as SLE in the prevalence of concomitant rheumatic diseases and autoantibody profiles by sex and race/ethnicity underscoring comorbidities associated with SLE.</p